Basic Information
Rapiscan
Regulatory Information
EMEA/H/C/001176
Authorised
September 6, 2010
15
May 24, 2023
Company Information
Norway
GE Healthcare AS Nycoveien 1 NO-0485 Oslo
GE Healthcare AS
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication This medicinal product is for diagnostic use only. Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Rapiscan. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rapiscan.